Lixte Operating Income from 2010 to 2025
| LIXTW Stock | USD 0.03 0 2.86% |
Operating Income | First Reported 2006-03-31 | Previous Quarter -983.3 K | Current Value -613.5 K | Quarterly Volatility 474.3 K |
Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers, such as Other Operating Expenses of 2.7 M, Total Operating Expenses of 2.7 M or Depreciation And Amortization of 6.1 M, as well as many indicators such as Price To Sales Ratio of 56.09, Dividend Yield of 2.0E-4 or PTB Ratio of 5.8. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.
Lixte | Operating Income |
Latest Lixte Biotechnology's Operating Income Growth Pattern
Below is the plot of the Operating Income of Lixte Biotechnology Holdings over the last few years. Operating Income is the amount of profit realized from Lixte Biotechnology operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Lixte Biotechnology Holdings is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Lixte Biotechnology's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lixte Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Lixte Operating Income Regression Statistics
| Arithmetic Mean | (2,982,307) | |
| Geometric Mean | 2,157,156 | |
| Coefficient Of Variation | (59.55) | |
| Mean Deviation | 1,352,372 | |
| Median | (2,403,143) | |
| Standard Deviation | 1,775,954 | |
| Sample Variance | 3.2T | |
| Range | 6.7M | |
| R-Value | (0.75) | |
| Mean Square Error | 1.5T | |
| R-Squared | 0.56 | |
| Significance | 0.0008 | |
| Slope | (279,281) | |
| Total Sum of Squares | 47.3T |
Lixte Operating Income History
About Lixte Biotechnology Financial Statements
Lixte Biotechnology investors use historical fundamental indicators, such as Lixte Biotechnology's Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lixte Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Income | -3.6 M | -3.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.